Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 4, 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific executive transaction rather than a financial performance report.
Material Changes
The filing details a change in the shareholding of Mr. Roger Connor, a Person Discharging Managerial Responsibilities. On May 4, 2016, Mr. Connor exercised nil-cost options over 2,029 and 2,156 ordinary shares. These options were granted on February 28, 2013, and vested on February 28, 2016, under the GlaxoSmithKline Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the share transaction details.
Important Facts for Investors
- Transaction Type: Exercise of nil-cost options by a Person Discharging Managerial Responsibility.
- Executive Involved: Mr. Roger Connor.
- Shares Exercised: 2,029 and 2,156 ordinary shares.
- Shares Delivered: 2,178 shares (net of tax value).
- Share Price: Fair market value was £14.69 and £14.68 at the points of exercise.
- Plan Details: Options were part of the GlaxoSmithKline Deferred Annual Bonus Plan.